Carethes JM, Stoffel EM. Lynch syndrome and Lynch syndrome mimics: the growin complex landscape of hereditart colon cancer. World J Gastroenterol 2015, 21, 9253-9261.
Choi Y-H, Lakhal-Chaieb L, Kröl A, Yu B, Buchanan D, Ahnen D et al. Risks of colorectal cancer and cancer-related mortality in familial colorectal cancer type X and Lynch syndrome families. J Natl Cancer Inst 2019; e-pub ahead of print 30 October 2018; doi: 10.1093/jnci/djy159.
Engel G, Ferlay J, Cristensen N, Kejs AMT, Johannesen TB, Khan S et al. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 7.0 (17.12.2014). Association of the Nordic Cancer Registries, Danish Cancer Society, 2016, http://www.ancr.nu.
Engel C, Loeffler M, Steinke V, Rahner N, Holinski-Feder E, Dietmaier W et al. Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol 2012, 30, 4409-4415.
Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer. Am J Gastroenterol 2014, 109, 1159-1179.
Hampel H, Stephens JA, Pukkala E, Sankila R, Aaltonen LA, Mecklin JP et al. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 2005, 129, 415-421.
Hatfield E, Green JS, Woods MO, Warden G, Parfrey PS. Impact of colonoscopic screening in Familial Colorectal Cancer Type X. Mol Genet Genomic Med. 2018, 6, 1021-1030.
Helder-Woolderink JM, Blok EA, Vasen HF, Hollema H, Mourits MJ, De Bock GH. Ovarian cancer in Lynch syndrome; a systematic review. Eur J Cancer 2016, 55, 65-73.
Jarvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K, Peltomaki P, Aaltonen LA, Mecklin JP. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 2009, 27, 4793-4797.
Joost P, Therkildsen C, Dominguez-Valentin M, Jonsson M, Nilbert M. Urinary Tract Cancer in Lynch Syndrome; Increased Risk in Carriers of MSH2 Mutations. Urology 2015, 86, 1212-1217.
Kastrinos F, Mukherjee B, Tayob N, Wang F, Sparr J, Raymond VM et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA 2009, 302, 1790-1795.
Ku CS, Cooper DN, Wu M, Roukos DH, Pawitan Y, Soong R et al. Gene discovery in familial cancer syndromes by exome sequencing: prospects for the elucidation of familial colorectal cancer type X. Mod Pathol. 2012, 25,1055-1068.
Lindberg LJ, Ladelund S, Frederiksen BL, Smith-Hansen L, Bernstein I. Outcome of 24 years national surveillance in different hereditary colorectal cancer subgroups leading to more individualised surveillance. J Med Genet 2016, 54, 297-304.
Lindor NM, Rabe K, Petersen GM, Haile R, Casey G, Baron J et al. Lower cancer incidence in Amseterdam-I criteria familes without mismatch repair deficiency; familial colorectal cancer type X. JAMA 2005, 293, 1979-1985.
Lu KH, Daniels M. Endometrial and ovarian cancer in women with Lynch syndrome: update in screening and prevention. Fam Cancer 2013, 12, 273-277.
Meyer LA, Broaddus RR, Lu KH. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control 2009, 16, 14-22.
Moller P, Seppala T, Bernstein I, Holinski-Feder E, Sala P, Evans DG et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut 2017, 66, 464-472.
R Core Team (2019) R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing: URL https://www.R-project.org/.
Raymond VM, Mukherjee B, Wang F, Huang SC, Stoffel EM, Kastrinos F et al. Elevated risk of prostate cancer among men with Lynch syndrome. J Clin Oncol 2013, 31, 1713-1718.
Rostgaard K. Methods for stratification of person-time and events - a prerequisite for Poisson regression and SIR estimation. Epidemiol Perspect Innov 2008, 5, 7.
Ryan S, Jenkins MA, Win AK. Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2014, 23, 437-449.
Therkildsen C, Ladelund S, Smith-Hansen L, Lindberg LJ, Nilbert M. Towards a gene- and gender-based risk estimates in Lynch syndrome; age-specific incidences for 13 extra-colorectal cancer types. Br J Cancer 2017, 117, 1702-1710.
Valle L. Genetic predisposition to colorectal cancer: where we stand and future perspectives. World J Gastroenterol. 2014, 20, 9828-9849.
Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 2013, 62, 812-823.
Warden G, Harnett D, Green J, Wish T, Woods MO, Green R et al. A population-based study of hereditary non-polyposis colorectal cancer: evidence of pathologic and genetic heterogeneity. Clin Genet. 2013, 84, 522-530.
Win AK, Lindor NM, Young JP, Macrae FA, Young GP, Williamson E et al. Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. J Natl Cancer Inst 2012, 104, 1363-1372.
Zetner DB, Bisgaard ML. Familial colorecal cancer type X. Curr Genomics 2017, 18, 341-359.